Lyra Therapeutics, Inc.

EFFECT effective

EFFECT effective

EFFECT effective

EFFECT effective

S-1 filed

EFFECT effective

EFFECT effective

EFFECT effective

EFFECT effective

424B4 priced

Lyra Therapeutics, Inc. is conducting its initial public offering (IPO) by selling 3,500,000 shares of common stock at $16.00 per share, with proceeds totaling $52.08 million. The company, a clinical-stage biotechnology firm, focuses on developing localized drug delivery solutions for ear, nose, and throat (ENT) diseases using its proprietary XTreo platform. Its lead candidates, LYR-210 and LYR-220, aim to treat chronic rhinosinusitis (CRS) with sustained drug delivery. The shares are listed on Nasdaq under 'LYRA,' and the company is an emerging growth company with reduced disclosure requirements. The IPO follows regulatory clearance of its investigational new drug application, though clinical trials face challenges from the COVID-19 pandemic.

EFFECT effective

Lyra Therapeutics, Inc. filed a Notice of Effectiveness for its S-1 registration statement, marking the culmination of its initial public offering (IPO) process. The filing confirms the effectiveness of its securities registration, enabling the company to proceed with trading its common stock on The Nasdaq Stock Market LLC. This follows an earlier 8-A12B filing, which outlined the registration of its common stock under Section 12(b) of the Securities Exchange Act.

S-1/A amended

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative drug and delivery solutions for ear, nose, and throat (ENT) diseases. The company's proprietary XTreo platform enables sustained, localized delivery of therapeutics, with initial products LYR-210 and LYR-220 targeting chronic rhinosinusitis (CRS). The S-1/A filing reflects updates to the IPO structure, including revised offering terms, clinical trial timelines, and explicit acknowledgment of the impact of the COVID-19 pandemic on operations. The company remains in Phase 2 trials for LYR-210 and plans Phase 1 trials for LYR-220, with anticipated data releases by late 2020 and 2021, respectively.

8-A12B effective

Lyra Therapeutics, Inc. filed Form 8-A12B to register its common stock for trading on The Nasdaq Stock Market LLC, referencing its prior S-1 registration statement. The filing incorporates by reference the prospectus from the S-1, indicating the company is proceeding with its initial public offering (IPO) process. No new material details are provided beyond confirming the registration of securities under Section 12(b) of the Exchange Act.

S-1 filed

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel drug and delivery solutions for ear, nose, and throat (ENT) diseases, particularly chronic rhinosinusitis (CRS). The company's proprietary XTreo platform enables sustained, localized drug delivery via bioresorbable polymeric matrices. LYR-210, a drug-eluting implant for CRS, is in a Phase 2 trial (LANTERN), with Phase 1 results showing safety and efficacy. The company is conducting an IPO to raise up to $57.5 million, targeting the Nasdaq Global Market under the symbol LYRA.

DRS/A amended

Lyra Therapeutics, Inc. is conducting an initial public offering (IPO) for its common stock, aiming to raise capital through the sale of shares. The company is a clinical-stage biotechnology firm focused on developing localized drug delivery solutions for ear, nose, and throat (ENT) diseases, particularly chronic rhinosinusitis (CRS). Its proprietary XTreo platform enables sustained drug release via bioresorbable polymeric matrices, with product candidates LYR-210 and LYR-220 in clinical trials. The offering includes underwriters like BofA Securities and Jefferies, with shares expected to trade on Nasdaq under 'LYRA' post-IPO. The company highlights its emerging growth status and risks associated with clinical trials, regulatory approvals, and market competition.

DRS/A amended

Lyra Therapeutics, Inc. is conducting an initial public offering (IPO) to raise capital through the sale of its common stock. The company focuses on developing novel drug and delivery solutions for ear, nose, and throat (ENT) diseases, particularly chronic rhinosinusitis (CRS). Its proprietary XTreo platform enables sustained, localized drug delivery via bioresorbable implants (LYR-210 and LYR-220). The offering includes underwriting details, expected Nasdaq listing, and disclosures about emerging growth company status. The prospectus highlights risks related to clinical trials, regulatory approval, and market competition.

DRS filed

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel drug and delivery solutions for the localized treatment of ear, nose, and throat (ENT) diseases. The company's proprietary XTreo platform enables sustained, targeted delivery of medications via biodegradable polymeric matrices. Its lead candidates, LYR-210 and LYR-220, are designed to provide up to six months of continuous drug therapy for chronic rhinosinusitis (CRS) patients. The company is conducting Phase 2 trials for LYR-210 and plans to initiate Phase 1 trials for LYR-220. This filing represents Lyra's initial public offering (IPO), with shares expected to trade on the Nasdaq Global Market under the symbol 'LYRA.'